МЕСТО ПЛАЗМАФЕРЕЗА В ЛЕЧЕНИИ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙ

1. Campion E. Desperate diseases and plasmapheresis. N.Engl.J.Med.,1992, 326,1425–1427

2. Von Baeyer H. Plasmapheresis in immune hematology: review of clinical outcome data with respect to evidence-based medicine and clinical experience.Ther. Apher. Dial., 2003, 7(1),127-40

3. Lewis EJ. Plasmapheresis in collagen vascular diseases. Ther. Apher., 1999 3(2), 172-177

4. Pagnoux C., Korach J.-M. , Guillevin. L. Indications for plasma exchange in systemic lupus erythematosus in 2005. Lupus, 2005, 14, 871-877.

5. Jones J.V., Robinson M.F., Parciany R.K. et al. Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA. Arthr. Rheum., 1981, 24, 1113–1120

6. Rifle G., Mousson C., Tanter Y. Hemapheresis in systemic lupus erythematosus. Clin. Exp. Rheumatol., 1990, 8(suppl. 5), 51–55

7. Soltesz P., Aleksza M., Antal-Szalmas P. et al. Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines. Autoimmun., 2002, 35(1),51–56

8. Jones J.V.,Cumming R.H.,Bacon P.A. et al. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus.QJ Med., 1979, 48,555–576.

9. Bonomini V., Vangelista A., Frasca G.M. et al. Effect of plasmapheresis on cellular immunity abnormalitiesin patients with systemic lupus erythematosus. Clin. Nephrol., 1984, 22,121–126

10. Lewis E.J.. Plasmapheresis for the treatment of severe lupus nephritis:uncontrolled observations. Am. J. Kidney Dis., 1982, 2,182–187

11. Wallace D.J. Apheresis for lupus erythematosus. Lupus; 1999;8(3),174-80

12. Lewis E.J., Hunsicker L.G., Lan S.P. et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N. Engl. J. Med., 1992, 326,1373–1379

13. Mistry-Burchardi N., Schonermarck U., Samtleben W. Apheresis in lupus nephritis. Ther. Apher., 2001, 5(3),161-170.

14. Nakamura T., Ushiyama C., Hara M. et al. Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis. Clin. Nephrol., 2002, 57(2),108-113

15. Schroeder J.O., Euler H.H., Loffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann. Intern. Med., 1987, 107, 344–346.

16. Euler H.H., Schroeder J.O. Antibody depletion and cytotoxic drug therapy in severe systemic lupus erythematosus. Transfus. Sci., 1992, 13, 167–184

17. Danieli M.G., Palmieri C., Salvi A. et al. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J. Clin. Apher., 2002,17(2),72-77.

18. Euler H.H., Schroeder J.O., Harten P. et al. Treatmentfree remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthr. Rheum., 1994, 37(12),1784-1794.

19. Dau P.C., Callahan J., Parker R., Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J. Rheumatol., 1991,18(2),270-276

20. Hanly J.G., Hong C., Zayed E. et al. Immunomodulating effects of synchronized plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus, 1995,4(6),457-463

21. Wallace D.J., Goldfinger D., Pepkowitz S.H. et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J. Clin. Apher., 1998, 13,163–166

22. Danieli M.G., Palmieri C., Salvi A. et al. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J. Clin. Apher., 2002, 17,72–77

23. Saracyn M., Korsak J., Wankowicz Z. Plasmapheresis in a case of necessary discontinuation of cyclophosphamide in the treatment of severe lupus nephritis. Pol. Merkuriusz Lek., 2004,17(98),162-164.

24. Mistry-Burchardi N., Schonermarck U., Samtleben W. Apheresis in lupus nephritis. Ther. Apher., 2001 Jun,5(3),161-170

25. Hristea D., Hadaya K., Marangon N. et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl. Int., 2007, 20(1),102-105

26. Stegmayr B., Korach J.M., Norda R. et al. Is there a need for a national or a global apheresis registry? Trans. Apher., Sci., 2003, 29, 179–185.

27. Norda R., Stegmayr B.G. Apheresis registry in Sweden, scope, techniques and indications for treatment. A report from the Swedish Apheresis Study Group. Trans. Apher. Sci., 2001, 24, 49–55

28. Raj R., Murin S,. Matthay R.A., Wiedemann H.P. Systemic lupus erythematosus in the intensive careunit. Crit. Care Clin., 2002, 18, 781–803.

29. Wallace D.J. Apheresis for lupus erythematosus: state of the art. Lupus, 2001, 10, 193–196

30. Braun-Moscovici Y., Furst. D.E. Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it? Curr. Opin. Rheumatol., 2003, 15,197–204

31. Hoshi K., Matsuda M., Ishikawa M. et al. Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clin . Rheumatol., 2004,23(3),252-255.

32. Badsha H., Teh C.L., Kong K.O. et al. Pulmonary hemorrhage in systemic lupus erythematosus. Semin. Arthr. Rheum., 2004, 33(6),414-421

33. Jennekens F.G.I., Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatol., 2002, 41,605-618

34. Vadacca M., Buzzulini F., Rigon A. et al., Neuropsychiatric lupus erythematosus. Reumatismo, 2006,58(3),177-186)

35. Neuwelt C.M. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther. Apher. Dial., 2003, 7(2),173-182.

36. Hanly J.G., Harrison M.J. Management of neuropsychiatric lupus. Best Pract. Res. Clin. Rheumatol., 2005,19(5),799-821

37. Espinosa G., Bucciarelli S., Cervera R. et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann.Rheum. Dis., 2004, 63, 730–736.

38. Bray V.J.,West S.G., Kristo D.A. Simultaneous presentation of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med. J., 1994, 87, 827–830.

39. Levine S., Shearn M.A. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Arch. Intern. Med., 1964, 113,826– 836.

40. Brunner H.I., Freedman M., Silverman E.D. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthr. Rheum 1999, 42, 2346–2355.

41. Guvenc B., Unsal C., Gurkan E. et.al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report. Transfus. Apher. Sci., 2004,31(1),17-20.

42. Aleem A., Al-Sugair S. Thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Acta Haematol., 2006,115 (1- 2), 68-73.

43. Masseau A., Guitton C., Bretonniere C . et al. Plasma exchanges as treatment of severe acute immune thrombocytopenic purpura. Rev. Med . Interne, 2005,26(10),824-826.

44. Song H.J., Suh Y.J., Suh C.H. Synchronization of plasma-pheresis and pulse cyclophosphamide in the treatment of thrombotic thrombocytopenic purpura and SLE associated with pregnancy. Clin. Exp .Rheumatol., 2003,21(4),523.

45. Stricker R.B., Davis J.A., Gershow J. et al. Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus. Case report and literature review from the plasmapheresis era. J. Rheumatol.,1992, 19,1469–1473

46. Asherson R.A., Espinosa G., Cervera R. et al., Catastrophic Antiphospholipid Syndrome: Proposed Guidelines for Diagnosis and Treatment. J. Clin . Rheumatol., 2002, 8(3),157-165

47. Castro P., Venegas R., Fardella P. et al. Catastrophic antiphospholipid syndrome and acute heart failure. Report of a case. Rev. Med. Chil., 2003,131(9),1037- 1041.

48. Cervera R., Asherson R.A., Font J. Catastrophic antiphospholipid syndrome. Rheum. Dis. Clin. North Am., 2006,32(3),575-590

49. Ahn E.R., Lander G., Bidot C.J. et al., Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am. J. Hematol., 2005,78(2),127-129

50. Van Eer M.Y,. Netten P.M., Schrijver G. et al. Sjogren’ssyndrome complicated by cryoglobulinemia and acute renal failure. Neth. J. Med., 1991, 39,23– 27.

51. Васильев В.И., Соловьев С.К., Чикликчи А.С. и соавт. Положительный эффект комбинированной терапии (плазмаферез в комбинации с пульс-терапией) на течение криоглобулинемического нефрита и язвенно-некротического васкулита при болезни Шегрена. Тер.aрхив., 1987,59,54-59

52. Guillevin L.,Fain O.,Lhote F. et al. Lack of superiority of steroids plus plasma Exchange to steroids alone in the treatment of polyarteritis nodosa and Churg- Strauss syndrome. A prospective randomized trial in 78 patients. Arthr. Rheum., 1992, 35,208–215.

53. Guillevin L.,LhoteF., Cohen P. et al. Lack of superiority of corticosteroids plus pulse cyclophosphamide and plasma exchanges to corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg- Strauss syndrome patients with poor prognostic factors. A prospective randomized trial in sixty-two patients. Arthr. Rheum., 1995, 38,1638–1645.

54. Stegmayr B.G., Almroth G., Berlin G. et al. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Int. J. Artif. Organs, 1999, 22,81–87

55. Gaskin G., Pusey C.D. Plasmapheresis in antineutrophil cytoplasmic antibodies-associated systemic vasculitis. Ther. Apher. 2001, 5,176–181

56. Caldwell J., Gendreau R.M., Furst D. A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid Arthr. J. Rheumatol., 1999, 26(8),1657–1662

57. Felson D.T., LaValley M.P., Baldassare A.R. et al.. The Prosorba column for treatment of refractory rheumatoid Arthritis: a randomized, doubleblind, shamcontrolled trial. Arthr. Rheum., 1999, 42(10),2153–2159

58. Gendreau R.M. A randomized double-blind shamcontrolled trial of the Prosorba column for treatment of refractory rheumatoid arthritis.. Ther. Apher., 2001, 5(2),80–83

59. Miller F.W., Leitman S.F., Cronin M.E. et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N. Engl. J . Med., 1992, 326,1380–1386

60. Mori M., Tomono N., Yokota S. Coronary arteritis of Kawasaki Disease unresponsive to high dose intravenous gammaglobulin successfully treated with plasmapheresis. Nikon Rinsho Meneki Gakkai Kaishi, 1995, 18,282–288

61. Mistry-Burchardi N., Schonermarck U., Samtleben W. Apheresis in lupus nephritis.Ther. Apher., 2001, 5,161–170

62. Aringer M., Smolen J.S., Graninger W.B. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthr. Rheum., 1998, 41, 414–420

63. Pohl M.A., Lan S.P., Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann. Intern. Med., 1991, 114, 924–929

64. Асеева Е.А.., Соловьев С.К.,Чикликчи А.С., Насонова В.А. Синхронная программная интенсивная терапия у больных с тяжелым течением ревматоидного артрита. Тер. архив, 2002. 5, 112-118.